Literature DB >> 26063036

miR-215 overexpression distinguishes ampullary carcinomas from pancreatic carcinomas.

Dong Ho Choi1, Sang Jae Park, Hark Kyun Kim.   

Abstract

Distinguishing ampullary carcinoma from pancreatic carcinoma is important because of their different prognoses. microRNAs are differentially expressed according to the tissue of origin. However, there is rare research on the differential diagnosis between the two types of cancers by microRNA in periampullary cancers. The present study was undertaken to compare microRNA profiles between ampullary and pancreatic carcinomas using microarrays. miR-215 was most significantly overexpressed in ampullary carcinomas; whereas the expressions of miR-134 and miR-214 were significantly lower in ampullary carcinomas than in pancreatic carcinomas. When these discriminatory microRNAs were applied to liver metastases, they were correctly predicted for the tissue of origin. Although this study is limited by small sample size, striking difference in microRNA expression and concordant expression of discriminating microRNAs in primary tumors and metastases suggest that these novel discriminatory microRNAs warrant future validation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26063036     DOI: 10.1016/s1499-3872(15)60368-x

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  7 in total

1.  MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.

Authors:  Weihua Chang; Menggang Liu; Jianhua Xu; Hangwei Fu; Bo Zhou; Tao Yuan; Ping Chen
Journal:  Tumour Biol       Date:  2016-09-16

2.  MicroRNA-215 targets NOB1 and inhibits growth and invasion of epithelial ovarian cancer.

Authors:  Yang Lin; Yang Jin; Tianmin Xu; Shunqing Zhou; Manhua Cui
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

3.  MicroRNA-215-3p Suppresses the Growth, Migration, and Invasion of Colorectal Cancer by Targeting FOXM1.

Authors:  Xiaowei Tang; Xianfeng Shi; Nianfei Wang; Wanren Peng; Zhendong Cheng
Journal:  Technol Cancer Res Treat       Date:  2019 Jan-Dec

4.  miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1.

Authors:  Jihua Han; Meiyin Zhang; Chunlei Nie; Jinliang Jia; Fengyue Wang; Jiawei Yu; Wen Bi; Bo Liu; Ruinan Sheng; Guoqing He; Lingyu Kong; Lingling Zheng; Rui Pang; Zhaoming Ding; Lili Chen; Qiang Guan; Shangha Pan; Xianzhi Meng; Jin Xu; Lianxin Liu; Jiewu Zhang
Journal:  Cell Death Dis       Date:  2019-02-27       Impact factor: 8.469

Review 5.  Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers.

Authors:  Pablo Letelier; Ismael Riquelme; Alfonso H Hernández; Neftalí Guzmán; Jorge G Farías; Juan Carlos Roa
Journal:  Int J Mol Sci       Date:  2016-05-23       Impact factor: 5.923

6.  MicroRNA-222 Controls Human Pancreatic Cancer Cell Line Capan-2 Proliferation by P57 Targeting.

Authors:  Yingying Zhao; Yuqiong Wang; Yuefeng Yang; Jingqi Liu; Yang Song; Yan Cao; Xiaoyu Chen; Wenzhuo Yang; Fei Wang; Jun Gao; Zhaoshen Li; Changqing Yang
Journal:  J Cancer       Date:  2015-10-16       Impact factor: 4.207

7.  Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.

Authors:  Kazuma Ohyashiki; Tomohiro Umezu; Seiichiro Katagiri; Chiaki Kobayashi; Kenko Azuma; Tetsuzo Tauchi; Seiichi Okabe; Yutaka Fukuoka; Junko H Ohyashiki
Journal:  Int J Mol Sci       Date:  2016-04-15       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.